Revelation Biosciences (REVB) stock

Market cap $14.1MShares as of Aug 3

$3.54

-6.73%

As of 7:28 PM ET after-hours, delayed 15+ min · Live for Pro members

Not scored

Breakaway doesn't score REVB. It is too small and too thinly traded for a fair Quality Score.

Healthcare · Biotech

NextEnd of 2026“Our focus remains on starting enrollment by year-end…”Trial start · SEC filing · Aug 6

Cash$11.5M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “through the first quarter of 2027”

Follow REVB's news. Pro members can get an alert when Revelation Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when REVB files newsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.

Cash$11.5M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “through the first quarter of 2027”

What's next for REVB, and how long its cash lasts

Next step the company has named

End of 2026“Our focus remains on starting enrollment by year-end, for the benefit of those patients and, ultimately, to deliver value for our shareholders.”Trial start · SEC filing · Aug 6

What it means: when a trial begins, or reaches the stage the company named.

For Pro members: 48 filings.

Cash runway Jun 30 balance sheet

About 4 quarters

$11.5M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “through the first quarter of 2027” (8-K, Aug 6).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Jul 19, 2024)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when James Rolke buys or sells

For Pro members: every trade, and James Rolke’s 10 filings and quotes.

Get an alert when REVB files newsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

REVB's latest filings

A change of officers or directors8-K, filed Aug 19
5 insider filingsForm 4, filed Aug 18
Quarterly report10-Q, filed Aug 6

21 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why REVB isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. REVB is worth about $14.1M and trades about 22,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.